Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 3/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | AR | P10275 | 1/20 | 0.64 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.64 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.64 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.64 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.44 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6843336 | 0.86 | PGR (0.69) | PGRCYP3A4ALDH1A1CYP2C19AR | |
| SCHEMBL6843333 | 0.86 | PGR (0.69) | PGRCYP3A4ALDH1A1CYP2C19AR | |
| SCHEMBL8396014 | 0.84 | PGR (0.66) | PGRCYP3A4ALDH1A1CYP2C19AR | |
| SCHEMBL19628769 | 0.84 | PGR (0.66) | PGRCYP3A4ALDH1A1CYP2C19AR | |
| SCHEMBL11326826 | 0.84 | PGR (0.66) | PGRCYP3A4ALDH1A1CYP2C19AR | |
| SCHEMBL10897035 | 0.83 | PGR (0.67) | PGRCYP3A4ALDH1A1CYP2C19AR | |
| SCHEMBL23638424 | 0.83 | PGR (0.67) | PGRCYP3A4ALDH1A1CYP2C19AR | |
| SCHEMBL19625918 | 0.83 | PGR (0.67) | PGRCYP3A4ALDH1A1CYP2C19AR | |
| SCHEMBL19625822 | 0.83 | PGR (0.67) | PGRCYP3A4ALDH1A1CYP2C19AR | |
| SCHEMBL7349633 | 0.82 | PGR (0.64) | PGRCYP3A4ALDH1A1CYP2C19AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0973791-A2 | PROCESS FOR PREPARATION OF 7 ALPHA-CARBOXYL 9, 11-EPOXY STEROIDS AND INTERMEDIATES USEFUL THEREIN AND A GENERAL PROCESS FOR THE EPOXIDATION OF OLIFINIC DOUBLE BONDS | G.D. Searle & Co. (US) | 2000-01-26 | — | — | EP | claimed |
| WO-1997021720-A2 | PROCESSES FOR PREPARATION OF 7 ALPHA-CARBOXYL 9,11-EPOXY STEROIDS AND INTERMEDIATES USEFUL THEREIN AND A GENERAL PROCESS FOR THE EPOXIDATION OF OLIFINIC DOUBLE BONDS | G.D. SEARLE AND CO. (US) | 1997-06-19 | — | — | WO | claimed |
| US-20050003473-A1 | Aspergillus ochraceus 11 alpha hydroxylase and oxidoreductase | PHARMACIA CORPORATION | 2005-01-06 | — | — | US | disclosed |
| EP-1352054-A2 | ASPERGILLUS OCHRACEUS 11 ALPHA HYDROLASE AND OXIDOREDUCTASE | Pharmacia Corporation (US) | 2003-10-15 | — | — | EP | disclosed |
| WO-2002046386-A2 | ASPERGILLUS OCHRACEUS 11 ALPHA HYDROXYLASE AND OXIDOREDUCTASE | PHARMACIA CORPORATION (US) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050003473-A1 | Aspergillus ochraceus 11 alpha hydroxylase and oxidoreductase | CYP21A2, CYP11B1, CYP17A1 | PGR 2693/4885CYP3A4 86/4885ALDH1A1 167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.